Through the new collaboration, the companies say they have developed an integration to bring together Medigate's in-depth IoMT visibility, anomaly detection and lifecycle management capabilities with Forescout’s enterprise device visibility, automated segmentation and incident response capabilities.
The collaboration will also see Forescout resell the Medigate Platform.
“Connected medical devices represent a fast-growing threat attack vector and the lack of device manufacturer standardisation and interoperability has created a significant problem for clinical care network operations,” said Pedro Abreu, chief product and strategy officer, Forescout.
“The combination of Medigate’s deep knowledge of medical devices and the healthcare industry with Forescout’s breadth of device intelligence adds a new level of cohesive device insight, expertise and security for the healthcare industry.”
“The Medigate and Forescout partnership and integration provide healthcare organisations with rich contextual visibility into their IT and clinical networks, as well as sophisticated network analysis to detect threats and implement clinically-driven policies,” said Jonathan Langer, co-founder and CEO, Medigate.
“These actionable insights will, in turn, reduce risk and improve patient safety.”
Medigate enables IT, info security, biomedical and clinical engineering teams to identify, monitor and secure every medical device on the clinical network.
Forescout says that by utilising Medigate’s “context-rich medical device classification and information”, it will enforce granular access control, segmentation and other compliance policies for clinical networks.
Forescout announced it will also extend these capabilities across all other connected devices in the health delivery organisation for a “cohesive, centralised device visibility and control platform”.